AU2010295509A1 - Buffers for controlling the pH of bone morphogenetic proteins - Google Patents
Buffers for controlling the pH of bone morphogenetic proteins Download PDFInfo
- Publication number
- AU2010295509A1 AU2010295509A1 AU2010295509A AU2010295509A AU2010295509A1 AU 2010295509 A1 AU2010295509 A1 AU 2010295509A1 AU 2010295509 A AU2010295509 A AU 2010295509A AU 2010295509 A AU2010295509 A AU 2010295509A AU 2010295509 A1 AU2010295509 A1 AU 2010295509A1
- Authority
- AU
- Australia
- Prior art keywords
- solution
- bmp
- glycylglycine
- solid composition
- buffer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000872 buffer Substances 0.000 title claims abstract description 73
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 title claims description 68
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 title claims description 68
- 229940112869 bone morphogenetic protein Drugs 0.000 title claims description 67
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 claims abstract description 100
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 68
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 67
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims abstract description 59
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims abstract description 48
- 108010008488 Glycylglycine Proteins 0.000 claims abstract description 45
- 229940043257 glycylglycine Drugs 0.000 claims abstract description 45
- 235000002906 tartaric acid Nutrition 0.000 claims abstract description 43
- 239000011975 tartaric acid Substances 0.000 claims abstract description 43
- 239000000243 solution Substances 0.000 claims description 88
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 claims description 49
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 claims description 49
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 45
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 45
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 39
- 239000008247 solid mixture Substances 0.000 claims description 33
- 239000003963 antioxidant agent Substances 0.000 claims description 24
- 230000003078 antioxidant effect Effects 0.000 claims description 24
- 235000006708 antioxidants Nutrition 0.000 claims description 24
- 235000000346 sugar Nutrition 0.000 claims description 24
- 229930182817 methionine Natural products 0.000 claims description 23
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 19
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 18
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 claims description 18
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 16
- 239000007999 glycylglycine buffer Substances 0.000 claims description 15
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims description 14
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 14
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 12
- 108010090254 Growth Differentiation Factor 5 Proteins 0.000 claims description 12
- 102100035379 Growth/differentiation factor 5 Human genes 0.000 claims description 12
- 229930195725 Mannitol Natural products 0.000 claims description 12
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 12
- 239000000594 mannitol Substances 0.000 claims description 12
- 235000010355 mannitol Nutrition 0.000 claims description 12
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims description 11
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 11
- 150000003892 tartrate salts Chemical class 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 10
- 239000003381 stabilizer Substances 0.000 claims description 10
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 9
- 108010024636 Glutathione Proteins 0.000 claims description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 9
- 229930006000 Sucrose Natural products 0.000 claims description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 9
- 229960003180 glutathione Drugs 0.000 claims description 9
- 239000008101 lactose Substances 0.000 claims description 9
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 claims description 9
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 9
- 239000005720 sucrose Substances 0.000 claims description 9
- 229940035024 thioglycerol Drugs 0.000 claims description 9
- 102100035368 Growth/differentiation factor 6 Human genes 0.000 claims description 8
- 235000010323 ascorbic acid Nutrition 0.000 claims description 8
- 229960005070 ascorbic acid Drugs 0.000 claims description 8
- 239000011668 ascorbic acid Substances 0.000 claims description 8
- 239000004471 Glycine Substances 0.000 claims description 7
- 102100035363 Growth/differentiation factor 7 Human genes 0.000 claims description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 7
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 7
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 7
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 7
- 235000003969 glutathione Nutrition 0.000 claims description 7
- 125000000647 trehalose group Chemical group 0.000 claims description 7
- 239000004474 valine Substances 0.000 claims description 7
- 108010049976 Bone Morphogenetic Protein 5 Proteins 0.000 claims description 6
- 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 claims description 6
- 102100022526 Bone morphogenetic protein 5 Human genes 0.000 claims description 6
- 108010090250 Growth Differentiation Factor 6 Proteins 0.000 claims description 6
- 101710204283 Growth/differentiation factor 7 Proteins 0.000 claims description 6
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 6
- 229960000310 isoleucine Drugs 0.000 claims description 6
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 238000003860 storage Methods 0.000 claims description 5
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 4
- 229960004452 methionine Drugs 0.000 claims description 4
- 235000006109 methionine Nutrition 0.000 claims description 4
- 239000012062 aqueous buffer Substances 0.000 claims description 2
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 claims 2
- 239000000203 mixture Substances 0.000 abstract description 120
- 238000009472 formulation Methods 0.000 abstract description 109
- 235000018102 proteins Nutrition 0.000 abstract description 60
- 210000000988 bone and bone Anatomy 0.000 abstract description 14
- 239000007788 liquid Substances 0.000 abstract description 11
- 230000000921 morphogenic effect Effects 0.000 abstract description 8
- 102100033808 Glycoprotein hormone alpha-2 Human genes 0.000 abstract description 6
- 101001069261 Homo sapiens Glycoprotein hormone alpha-2 Proteins 0.000 abstract description 6
- 102000007453 TGF-beta Superfamily Proteins Human genes 0.000 abstract 2
- 108010085004 TGF-beta Superfamily Proteins Proteins 0.000 abstract 2
- 229960001367 tartaric acid Drugs 0.000 description 38
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 18
- 150000001413 amino acids Chemical group 0.000 description 18
- 229940001447 lactate Drugs 0.000 description 18
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 17
- 229940095064 tartrate Drugs 0.000 description 17
- 230000002776 aggregation Effects 0.000 description 16
- 238000004220 aggregation Methods 0.000 description 16
- 239000004094 surface-active agent Substances 0.000 description 14
- 230000002188 osteogenic effect Effects 0.000 description 13
- 229920001213 Polysorbate 20 Polymers 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 12
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 12
- 229940068977 polysorbate 20 Drugs 0.000 description 12
- 238000000502 dialysis Methods 0.000 description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 210000000845 cartilage Anatomy 0.000 description 8
- 238000007429 general method Methods 0.000 description 8
- 208000014674 injury Diseases 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 7
- 230000007547 defect Effects 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 235000003704 aspartic acid Nutrition 0.000 description 5
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 229940126534 drug product Drugs 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000004310 lactic acid Substances 0.000 description 5
- 235000014655 lactic acid Nutrition 0.000 description 5
- 239000012669 liquid formulation Substances 0.000 description 5
- -1 lyophilizates Substances 0.000 description 5
- 239000001630 malic acid Substances 0.000 description 5
- 235000011090 malic acid Nutrition 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
- 229920000053 polysorbate 80 Polymers 0.000 description 5
- 229940068968 polysorbate 80 Drugs 0.000 description 5
- 239000001384 succinic acid Substances 0.000 description 5
- 235000011044 succinic acid Nutrition 0.000 description 5
- 150000008163 sugars Chemical class 0.000 description 5
- 102000008154 Bone Morphogenetic Protein 6 Human genes 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 4
- 201000008482 osteoarthritis Diseases 0.000 description 4
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000010392 Bone Fractures Diseases 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108010041881 Growth Differentiation Factor 10 Proteins 0.000 description 3
- 102100040895 Growth/differentiation factor 10 Human genes 0.000 description 3
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 description 3
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 3
- 108010056852 Myostatin Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000006193 liquid solution Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000012931 lyophilized formulation Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- 229920001992 poloxamer 407 Polymers 0.000 description 3
- 229940044476 poloxamer 407 Drugs 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 238000013060 ultrafiltration and diafiltration Methods 0.000 description 3
- YHBAZQDEMYQPJL-UHFFFAOYSA-N 2-[(2-aminoacetyl)amino]acetic acid;hydron;chloride Chemical compound Cl.NCC(=O)NCC(O)=O YHBAZQDEMYQPJL-UHFFFAOYSA-N 0.000 description 2
- 108010005853 Anti-Mullerian Hormone Proteins 0.000 description 2
- 102100037150 BMP and activin membrane-bound inhibitor homolog Human genes 0.000 description 2
- 108010049951 Bone Morphogenetic Protein 3 Proteins 0.000 description 2
- 102100028726 Bone morphogenetic protein 10 Human genes 0.000 description 2
- 101710118482 Bone morphogenetic protein 10 Proteins 0.000 description 2
- 102100024504 Bone morphogenetic protein 3 Human genes 0.000 description 2
- 102100022545 Bone morphogenetic protein 8B Human genes 0.000 description 2
- 206010061762 Chondropathy Diseases 0.000 description 2
- 208000003044 Closed Fractures Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102100040897 Embryonic growth/differentiation factor 1 Human genes 0.000 description 2
- 102100029379 Follistatin-related protein 3 Human genes 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 2
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 2
- 102100038353 Gremlin-2 Human genes 0.000 description 2
- 101710169778 Gremlin-2 Proteins 0.000 description 2
- 108010090296 Growth Differentiation Factor 1 Proteins 0.000 description 2
- 108010041834 Growth Differentiation Factor 15 Proteins 0.000 description 2
- 108010090290 Growth Differentiation Factor 2 Proteins 0.000 description 2
- 102000004858 Growth differentiation factor-9 Human genes 0.000 description 2
- 108090001086 Growth differentiation factor-9 Proteins 0.000 description 2
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 description 2
- 101710194452 Growth/differentiation factor 11 Proteins 0.000 description 2
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 101000740070 Homo sapiens BMP and activin membrane-bound inhibitor homolog Proteins 0.000 description 2
- 101000899361 Homo sapiens Bone morphogenetic protein 7 Proteins 0.000 description 2
- 101001062529 Homo sapiens Follistatin-related protein 3 Proteins 0.000 description 2
- 101001023964 Homo sapiens Growth/differentiation factor 6 Proteins 0.000 description 2
- 101001023968 Homo sapiens Growth/differentiation factor 7 Proteins 0.000 description 2
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 2
- 208000029725 Metabolic bone disease Diseases 0.000 description 2
- 101710167839 Morphogenetic protein Proteins 0.000 description 2
- 102000011830 Neural cell adhesion Human genes 0.000 description 2
- 108050002172 Neural cell adhesion Proteins 0.000 description 2
- 208000002565 Open Fractures Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 102100035194 Placenta growth factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 102000019307 Sclerostin Human genes 0.000 description 2
- 108050006698 Sclerostin Proteins 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 239000000868 anti-mullerian hormone Substances 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 108010027904 cartilage-derived-morphogenetic protein-2 Proteins 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000009295 crossflow filtration Methods 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000013020 final formulation Substances 0.000 description 2
- 239000012537 formulation buffer Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229940049920 malate Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 108700007229 noggin Proteins 0.000 description 2
- 102000045246 noggin Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000003239 periodontal effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000004845 protein aggregation Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 229940086735 succinate Drugs 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- UBWXUGDQUBIEIZ-UHFFFAOYSA-N (13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl) 3-phenylpropanoate Chemical compound CC12CCC(C3CCC(=O)C=C3CC3)C3C1CCC2OC(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 102100034111 Activin receptor type-1 Human genes 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 102000005606 Activins Human genes 0.000 description 1
- 108090000668 Annexin A2 Proteins 0.000 description 1
- 102100034613 Annexin A2 Human genes 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102100025440 BMP-binding endothelial regulator protein Human genes 0.000 description 1
- 102100028728 Bone morphogenetic protein 1 Human genes 0.000 description 1
- 108090000654 Bone morphogenetic protein 1 Proteins 0.000 description 1
- 102000003928 Bone morphogenetic protein 15 Human genes 0.000 description 1
- 108090000349 Bone morphogenetic protein 15 Proteins 0.000 description 1
- 101710117970 Bone morphogenetic protein 8B Proteins 0.000 description 1
- 102100025423 Bone morphogenetic protein receptor type-1A Human genes 0.000 description 1
- 101710120270 Bone morphogenetic protein receptor type-1A Proteins 0.000 description 1
- 101710120271 Bone morphogenetic protein receptor type-1B Proteins 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 241000202252 Cerberus Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 102100020921 Follistatin Human genes 0.000 description 1
- 108010014612 Follistatin Proteins 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 102100038367 Gremlin-1 Human genes 0.000 description 1
- 108010090293 Growth Differentiation Factor 3 Proteins 0.000 description 1
- 101710204270 Growth/differentiation factor 2 Proteins 0.000 description 1
- 102100035364 Growth/differentiation factor 3 Human genes 0.000 description 1
- 101710204281 Growth/differentiation factor 6 Proteins 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 101000799140 Homo sapiens Activin receptor type-1 Proteins 0.000 description 1
- 101000934632 Homo sapiens BMP-binding endothelial regulator protein Proteins 0.000 description 1
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 1
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 1
- 101000899388 Homo sapiens Bone morphogenetic protein 5 Proteins 0.000 description 1
- 101000899390 Homo sapiens Bone morphogenetic protein 6 Proteins 0.000 description 1
- 101000899368 Homo sapiens Bone morphogenetic protein 8B Proteins 0.000 description 1
- 101001032872 Homo sapiens Gremlin-1 Proteins 0.000 description 1
- 101001023988 Homo sapiens Growth/differentiation factor 5 Proteins 0.000 description 1
- 101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 description 1
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 206010061246 Intervertebral disc degeneration Diseases 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102100030173 Muellerian-inhibiting factor Human genes 0.000 description 1
- 101100165554 Mus musculus Bmp5 gene Proteins 0.000 description 1
- 101100165560 Mus musculus Bmp7 gene Proteins 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 201000009859 Osteochondrosis Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 108010082093 Placenta Growth Factor Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 102100022432 Sclerostin domain-containing protein 1 Human genes 0.000 description 1
- 101710169324 Sclerostin domain-containing protein 1 Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 102100034136 Serine/threonine-protein kinase receptor R3 Human genes 0.000 description 1
- 101710082813 Serine/threonine-protein kinase receptor R3 Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 101100472152 Trypanosoma brucei brucei (strain 927/4 GUTat10.1) REL1 gene Proteins 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 108010023082 activin A Proteins 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000002639 bone cement Substances 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 230000034127 bone morphogenesis Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008355 cartilage degradation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000002648 chondrogenic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 108010045487 coagulogen Proteins 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000003074 dental pulp Anatomy 0.000 description 1
- 230000013860 dentinogenesis Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 230000007941 heterotopic ossification Effects 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 102000045896 human BMP2 Human genes 0.000 description 1
- 102000046148 human BMP4 Human genes 0.000 description 1
- 102000046095 human BMP6 Human genes 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-LWMBPPNESA-N levotartaric acid Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 230000005499 meniscus Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
- 229940074439 potassium sodium tartrate Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- GPTFURBXHJWNHR-UHFFFAOYSA-N protopine Chemical compound C1=C2C(=O)CC3=CC=C4OCOC4=C3CN(C)CCC2=CC2=C1OCO2 GPTFURBXHJWNHR-UHFFFAOYSA-N 0.000 description 1
- 108700015048 receptor decoy activity proteins Proteins 0.000 description 1
- 108091008597 receptor serine/threonine kinases Proteins 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010955 robust manufacturing process Methods 0.000 description 1
- 210000002163 scaffold cell Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- CSMWJXBSXGUPGY-UHFFFAOYSA-L sodium dithionate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)S([O-])(=O)=O CSMWJXBSXGUPGY-UHFFFAOYSA-L 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 230000025934 tissue morphogenesis Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24338309P | 2009-09-17 | 2009-09-17 | |
| US61/243,383 | 2009-09-17 | ||
| PCT/US2010/049229 WO2011035094A1 (en) | 2009-09-17 | 2010-09-17 | Buffers for controlling the ph of bone morphogenetic proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2010295509A1 true AU2010295509A1 (en) | 2012-04-19 |
| AU2010295509A2 AU2010295509A2 (en) | 2012-05-03 |
Family
ID=43037185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2010295509A Abandoned AU2010295509A1 (en) | 2009-09-17 | 2010-09-17 | Buffers for controlling the pH of bone morphogenetic proteins |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20110224410A1 (enExample) |
| EP (1) | EP2352750B1 (enExample) |
| JP (1) | JP2013518808A (enExample) |
| AU (1) | AU2010295509A1 (enExample) |
| CA (1) | CA2774024A1 (enExample) |
| ES (1) | ES2387379T3 (enExample) |
| WO (1) | WO2011035094A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9169308B2 (en) | 2013-01-25 | 2015-10-27 | Warsaw Orthopedic, Inc. | Methods and compositions of human recombinant growth and differentiation factor-5 (rhGDF-5) isolated from inclusion bodies |
| US8945872B2 (en) | 2013-01-25 | 2015-02-03 | Warsaw Orthopedic, Inc. | Methods of purifying human recombinant growth and differentiation factor-5 (rhGDF-5) protein |
| US8956829B2 (en) | 2013-01-25 | 2015-02-17 | Warsaw Orthopedic, Inc. | Human recombinant growth and differentiaton factor-5 (rhGDF-5) |
| US9359417B2 (en) | 2013-01-25 | 2016-06-07 | Warsaw Orthopedic, Inc. | Cell cultures and methods of human recombinant growth and differentiaton factor-5 (rhGDF-5) |
| US9051389B2 (en) | 2013-01-25 | 2015-06-09 | Warsaw Orthopedic, Inc. | Expression conditions and methods of human recombinant growth and differentiation factor-5 (rhGDF-5) |
| GB201906917D0 (en) * | 2019-05-16 | 2019-07-03 | Intract Pharma Ltd | Novel compositions |
| CN114276407B (zh) * | 2021-12-29 | 2023-08-15 | 浙江旅游职业学院 | 一种采用ph偏移技术从骨或壳内提取蛋白质的设备及方法 |
| CN116549656A (zh) * | 2023-05-25 | 2023-08-08 | 深圳奥礼生物科技有限公司 | 一种提高司美格鲁肽在肠道中稳定性的组合物 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL83003A (en) | 1986-07-01 | 1995-07-31 | Genetics Inst | Osteoinductive factors |
| US6919308B2 (en) | 1988-04-08 | 2005-07-19 | Stryker Corporation | Osteogenic devices |
| US5011691A (en) | 1988-08-15 | 1991-04-30 | Stryker Corporation | Osteogenic devices |
| US5266683A (en) | 1988-04-08 | 1993-11-30 | Stryker Corporation | Osteogenic proteins |
| CA2085134C (en) | 1990-06-15 | 2003-03-18 | Carnegie Institution Of Washington | Gdf-1 |
| US6949505B1 (en) | 1991-03-11 | 2005-09-27 | Curis, Inc. | Morphogen-induced dendritic growth |
| US6800603B2 (en) | 1991-03-11 | 2004-10-05 | Curis, Inc. | Morphogen-induced neural cell adhesion |
| US6506729B1 (en) | 1991-03-11 | 2003-01-14 | Curis, Inc. | Methods and compositions for the treatment and prevention of Parkinson's disease |
| US5656593A (en) | 1991-03-11 | 1997-08-12 | Creative Biomolecules, Inc. | Morphogen induced periodontal tissue regeneration |
| US5674844A (en) | 1991-03-11 | 1997-10-07 | Creative Biomolecules, Inc. | Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases |
| US5849686A (en) | 1991-03-11 | 1998-12-15 | Creative Biomolecules, Inc. | Morphogen-induced liver regeneration |
| US6287816B1 (en) | 1991-06-25 | 2001-09-11 | Genetics Institute, Inc. | BMP-9 compositions |
| WO1993009229A1 (en) | 1991-11-04 | 1993-05-13 | Genetics Institute, Inc. | Recombinant bone morphogenetic protein heterodimers, compositions and methods of use |
| DK0625989T3 (da) | 1992-02-12 | 2000-06-26 | Bioph Biotech Entw Pharm Gmbh | DNA-sekvenser kodende for hidtil ukendte vækst-/differentieringsfaktorer |
| CA2147598A1 (en) | 1992-11-03 | 1994-05-11 | Stryker Corporation | Op-3-induced morphogenesis |
| CA2153653C (en) | 1993-01-12 | 2010-12-07 | Se-Jin Lee | Growth differentiation factor-9 |
| EP0690871A4 (en) | 1993-01-12 | 1999-10-20 | Univ Johns Hopkins Med | GROWTH DIFFERENTIATION FACTOR-5 |
| DK0690873T3 (da) | 1993-03-19 | 2003-09-29 | Univ Johns Hopkins Med | Vækstdifferentieringsfaktor-8 |
| WO1994026892A1 (en) | 1993-05-12 | 1994-11-24 | Genetics Institute, Inc. | Bmp-11 compositions |
| JPH09501305A (ja) | 1993-05-12 | 1997-02-10 | ジェネティックス・インスティテュート・インコーポレイテッド | Ｂｍｐ−１０組成物 |
| WO1995001801A1 (en) | 1993-07-09 | 1995-01-19 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-6 |
| US6204047B1 (en) | 1993-10-08 | 2001-03-20 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-10 |
| JP3300500B2 (ja) | 1993-10-12 | 2002-07-08 | 新日本製鐵株式会社 | 疲労強度、降伏強度および被削性に優れる熱間鍛造用鋼の製造方法 |
| DE4334646C1 (de) | 1993-10-12 | 1994-09-29 | Quinting Friedhelm | Durchsichtige Analog-Zeituhr |
| AU689184B2 (en) | 1993-12-07 | 1998-03-26 | Genetics Institute, Llc | BMP-12, BMP-13 and tendon-inducing compositions thereof |
| US5399677A (en) | 1993-12-07 | 1995-03-21 | Genetics Institute, Inc. | Mutants of bone morphogenetic proteins |
| IL114397A0 (en) | 1994-07-01 | 1995-10-31 | Bioph Biotech Entw Pharm Gmbh | Growth/differentiation factor of the TGF-beta-family |
| EP1574577A3 (en) | 1994-07-08 | 2006-06-14 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-11 |
| AU1120295A (en) | 1994-11-07 | 1996-05-31 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Cartilage-derived morphogenetic proteins |
| US5635372A (en) | 1995-05-18 | 1997-06-03 | Genetics Institute, Inc. | BMP-15 compositions |
| EP0894004B2 (en) | 1996-03-22 | 2007-02-21 | Curis, Inc. | Method for enhancing functional recovery of motor coordination, speech or sensory perception after central nervous system ischemia or trauma |
| US6498142B1 (en) | 1996-05-06 | 2002-12-24 | Curis, Inc. | Morphogen treatment for chronic renal failure |
| US7041641B2 (en) | 1997-03-20 | 2006-05-09 | Stryker Corporation | Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects |
| US6958149B2 (en) | 1998-10-06 | 2005-10-25 | Stryker Corporation | Repair of larynx, trachea, and other fibrocartilaginous tissues |
| CA2345024C (en) | 1998-10-07 | 2009-05-19 | Stryker Corporation | Modified tgf-.beta. superfamily proteins |
| US6677432B1 (en) | 1998-10-07 | 2004-01-13 | Stryker Corporation | Mutations of the C-terminal portion of TGF-β superfamily proteins |
| US6846906B1 (en) | 1998-10-07 | 2005-01-25 | Stryker Corporation | Modified proteins of the TGF-β superfamily, including morphogenic proteins |
| EP1123081B1 (en) * | 1998-10-19 | 2002-12-11 | SYNTHES AG Chur | Hardenable ceramic hydraulic cement |
| EP1187602A4 (en) * | 2000-04-18 | 2004-09-15 | Peptron Inc | SUSTAINABLE RELEASE INJECTABLE PHARMACEUTICAL COMPOSITION AND METHODS OF PREPARING THE SAME |
| US6949251B2 (en) | 2001-03-02 | 2005-09-27 | Stryker Corporation | Porous β-tricalcium phosphate granules for regeneration of bone tissue |
| US7005136B2 (en) * | 2002-03-29 | 2006-02-28 | Ethicon, Inc. | Bone replacement materials utilizing bioabsorbable liquid polymers |
| US7026374B2 (en) * | 2002-06-25 | 2006-04-11 | Aruna Nathan | Injectable microdispersions for medical applications |
| CA2561809A1 (en) | 2004-03-31 | 2005-10-20 | Xencor, Inc. | Bmp-7 variants with improved properties |
| WO2005113585A2 (en) | 2004-05-20 | 2005-12-01 | Acceleron Pharma Inc. | Modified tgf-beta superfamily polypeptides |
| CA2567405A1 (en) | 2004-05-25 | 2005-12-08 | Stryker Corporation | Use of morphogenic proteins for treating cartilage defects |
| WO2007087053A2 (en) | 2005-12-22 | 2007-08-02 | Centocor, Inc | Bmp-7 variant compositions, methods and uses |
-
2010
- 2010-09-17 CA CA2774024A patent/CA2774024A1/en not_active Abandoned
- 2010-09-17 EP EP10755307A patent/EP2352750B1/en not_active Not-in-force
- 2010-09-17 WO PCT/US2010/049229 patent/WO2011035094A1/en not_active Ceased
- 2010-09-17 US US12/884,414 patent/US20110224410A1/en not_active Abandoned
- 2010-09-17 ES ES10755307T patent/ES2387379T3/es active Active
- 2010-09-17 AU AU2010295509A patent/AU2010295509A1/en not_active Abandoned
- 2010-09-17 JP JP2012529917A patent/JP2013518808A/ja active Pending
-
2012
- 2012-09-14 US US13/615,829 patent/US20130172254A1/en not_active Abandoned
-
2013
- 2013-11-25 US US14/088,623 patent/US20140336114A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2774024A1 (en) | 2011-03-24 |
| US20140336114A1 (en) | 2014-11-13 |
| ES2387379T3 (es) | 2012-09-21 |
| JP2013518808A (ja) | 2013-05-23 |
| US20130172254A1 (en) | 2013-07-04 |
| WO2011035094A1 (en) | 2011-03-24 |
| EP2352750A1 (en) | 2011-08-10 |
| AU2010295509A2 (en) | 2012-05-03 |
| US20110224410A1 (en) | 2011-09-15 |
| EP2352750B1 (en) | 2012-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20140336114A1 (en) | Buffers for Controlling the pH of Bone Morphogenetic Proteins | |
| AU2007339280B2 (en) | Sustained-release formulations comprising crystals, macromolecular gels, and particulate suspensions of biologic agents | |
| CA2361635C (en) | Methods and compositions for healing and repair of articular cartilage | |
| US6407060B1 (en) | Method for enhancing functional recovery following central nervous system ischemia or trauma | |
| JP5529754B2 (ja) | Ｎｏｇｇｉｎに対する感受性が低下したＢＭＰ変異体 | |
| US20110319328A1 (en) | Bone morphogenetic protein compositions | |
| US20070191276A1 (en) | Compositions and therapeutic methods using morphogenic proteins, hormones and hormone receptors | |
| JP2010069327A (ja) | 遺伝子治療による骨形成 | |
| US20110224138A1 (en) | Methods for treating pain induced by injuries and diseases of an articular joint | |
| US20130190236A1 (en) | BMP-7 Variants with Reduced Immunogenicity | |
| AU773990B2 (en) | Compositions and therapeutic methods using morphogenic proteins, hormones and hormone receptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 22 MAR 2012 |
|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |